{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:02:01Z","timestamp":1790146921984,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Progressive IgA nephropathy (IgAN) in childhood presents challenges for treatment. Telitacicept has shown significant benefits in adult IgAN patients, warranting investigation into its potential efficacy in the pediatric population. This study was designed to evaluate the changes in clinical parameters before and after telitacicept treatment in children with IgA nephropathy (IgAN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, self-controlled before-and-after study was conducted. Children received subcutaneous injections of telitacicept once weekly, in addition to ongoing background therapy (including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, glucocorticoids, and\/or other immunosuppressants). The primary clinical parameter was the change in 24-hour urinary protein (24-h UP) from baseline. Secondary clinical parameters included changes in serum albumin (ALB), immunoglobulins, CD19+ B-cell count, estimated glomerular filtration rate (eGFR), and immunosuppressant dosage. Adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven children were included. The 24-h UP level began a non-significant decline at week 4 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05) but continued to significantly decrease at weeks 12 and 24 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), whereas serum ALB levels tended to increase concurrently. Serum levels of IgG, IgA, and IgM exhibited a decreasing trend over time (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Compared with baseline, the reductions in all three immunoglobulin subtypes reached statistical significance at week 24 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.01), with IgA and IgM showing more pronounced decreases. The CD19+ B-cell count was significantly reduced at week 24 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). The eGFR remained stable throughout the treatment period (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). The glucocorticoid dosage tended to decrease during follow-up (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Adverse events were mild, primarily upper respiratory tract infections (4 episodes) and local injection site reactions (1 episode), with no serious adverse events reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In children with IgAN, telitacicept was associated with reduced proteinuria, facilitated immunosuppressant tapering, and demonstrated a favorable safety profile, while preserving renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1944384","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:20:58Z","timestamp":1790144458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiaoxia","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Youxi General Hospital","place":["Sanming, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rirong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"Iga nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ndt\/gfae252","article-title":"Long-term outcomes of IgA nephropathy in China","volume":"40","author":"Shen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cellimm.2006.08.002","article-title":"Gommerman JL.baff induces a hyper-iga syndrome in the intestinal lamina propria concomitant with iga deposition in the kidney independent of light","volume":"241","author":"McCarthy","year":"2006","journal-title":"Cell Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","article-title":"Tlr9 and baff: their expression in patients with iga nephropathy","volume":"10","author":"Li","year":"2014","journal-title":"Mol Med Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Li K-S.serum baff is elevated in patients with iga nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center b cells in iga nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"J Am Soc Nephro"},{"key":"B8","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3760\/cma.j.issn.0578-1310.2017.09.002","article-title":"Evidence-based guidelines for diagnosis and treatment of primary IgA nephropathy (2016)","volume":"55","year":"2017","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis","volume":"40","author":"Vivarelli","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","article-title":"KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"(2015) intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa2514415","article-title":"Telitacicept for IgA nephropathy - interim analysis of a phase 3 trial","volume":"394","author":"Lv","year":"2026","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00467-025-07023-6","article-title":"Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study","volume":"41","author":"Jin","year":"2026","journal-title":"Pediatr Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2664988","DOI":"10.1080\/0886022X.2026.2664988","article-title":"Research on the safty and efficacy of telitacicept in the treatment of IgA nephropathy in children","volume":"48","author":"Liang","year":"2026","journal-title":"Ren Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s13730-025-00983-6","article-title":"Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept","volume":"14","author":"Jin","year":"2025","journal-title":"CEN Case Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.2147\/DDDT.S565279","article-title":"Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis-associated nephritis in children: a retrospective single-centre study","volume":"19","author":"Zhou","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00467-025-06905-z","article-title":"Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series","volume":"40","author":"Wu","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10238-025-01829-2","article-title":"Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study","volume":"25","author":"Shu","year":"2025","journal-title":"Clin Exp Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2449580","DOI":"10.1080\/0886022X.2025.2449580","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a real-world study","volume":"47","author":"Dong","year":"2025","journal-title":"Ren Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s00467-025-06709-1","article-title":"Telitacicept use in children with IgA vasculitis nephritis: preliminary observations","volume":"40","author":"Wang","year":"2025","journal-title":"Pediatr Nephrol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1944384\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:21:00Z","timestamp":1790144460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1944384\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"alternative-id":["10.3389\/fped.2026.1944384"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1944384","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1944384"}}